Treatment of necrolytic migratory erythema in glucagonoma syndrome

Mary E. Shepherd; Sharon S. Raimer; S. K. Tyring; Edgar B. Smith

doi:10.1016/0190-9622(91)70285-A

Treatment of necrolytic migratory erythema in glucagonoma syndrome

Mary E. Shepherd, Sharon S. Raimer, S. K. Tyring, Edgar B. Smith

Dermatology

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

The glucagonoma syndrome is characterized by elevated serum glucagon, a pancreatic α-cell tumor, anemia, hypoaminoacidemia, and necrolytic migratory erythema. Necrolytic migratory erythema may cause marked morbidity and is frequently misdiagnosed. A 42-year-old white woman with a 1½-year history of refractory dermatitis (most severe on the lower extremities) had the glucagonoma syndrome. Her severe morbidity was markedly relieved with the administration of intravenous amino acids. This therapy was successful in controlling the necrolytic migratory erythema through recurrences after somatostatin (SMS 201-995), surgical debulking, and chemotherapy proved inadequate.

Original language	English (US)
Pages (from-to)	925-928
Number of pages	4
Journal	Journal of the American Academy of Dermatology
Volume	25
Issue number	5
DOIs	https://doi.org/10.1016/0190-9622(91)70285-A
State	Published - 1991

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/0190-9622(91)70285-A

Cite this

@article{68b13f64f7684599ab3dd807190507e5,

title = "Treatment of necrolytic migratory erythema in glucagonoma syndrome",

abstract = "The glucagonoma syndrome is characterized by elevated serum glucagon, a pancreatic α-cell tumor, anemia, hypoaminoacidemia, and necrolytic migratory erythema. Necrolytic migratory erythema may cause marked morbidity and is frequently misdiagnosed. A 42-year-old white woman with a 1½-year history of refractory dermatitis (most severe on the lower extremities) had the glucagonoma syndrome. Her severe morbidity was markedly relieved with the administration of intravenous amino acids. This therapy was successful in controlling the necrolytic migratory erythema through recurrences after somatostatin (SMS 201-995), surgical debulking, and chemotherapy proved inadequate.",

author = "Shepherd, {Mary E.} and Raimer, {Sharon S.} and Tyring, {S. K.} and Smith, {Edgar B.}",

note = "Funding Information: From the Departments of Dermatology{"} and Pediatrics,b University of Michigan Medical Center. Supported in part by the Babcock Dermatologic Endowment, Ann Ar-bor, Michigan. Presented in part at the Forty-ninth Annual Meeting of the American Academy of Dermatology. Atlanta, Ga., Dec. 1-6, 1990. Reprint requests; James E. Rasmussen, MD, Department of Derma-tology, University of Michigan Medical Center, 1910 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0314.",

year = "1991",

doi = "10.1016/0190-9622(91)70285-A",

language = "English (US)",

volume = "25",

pages = "925--928",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "5",

}

TY - JOUR

T1 - Treatment of necrolytic migratory erythema in glucagonoma syndrome

AU - Shepherd, Mary E.

AU - Raimer, Sharon S.

AU - Tyring, S. K.

AU - Smith, Edgar B.

N1 - Funding Information: From the Departments of Dermatology" and Pediatrics,b University of Michigan Medical Center. Supported in part by the Babcock Dermatologic Endowment, Ann Ar-bor, Michigan. Presented in part at the Forty-ninth Annual Meeting of the American Academy of Dermatology. Atlanta, Ga., Dec. 1-6, 1990. Reprint requests; James E. Rasmussen, MD, Department of Derma-tology, University of Michigan Medical Center, 1910 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0314.

PY - 1991

Y1 - 1991

N2 - The glucagonoma syndrome is characterized by elevated serum glucagon, a pancreatic α-cell tumor, anemia, hypoaminoacidemia, and necrolytic migratory erythema. Necrolytic migratory erythema may cause marked morbidity and is frequently misdiagnosed. A 42-year-old white woman with a 1½-year history of refractory dermatitis (most severe on the lower extremities) had the glucagonoma syndrome. Her severe morbidity was markedly relieved with the administration of intravenous amino acids. This therapy was successful in controlling the necrolytic migratory erythema through recurrences after somatostatin (SMS 201-995), surgical debulking, and chemotherapy proved inadequate.

AB - The glucagonoma syndrome is characterized by elevated serum glucagon, a pancreatic α-cell tumor, anemia, hypoaminoacidemia, and necrolytic migratory erythema. Necrolytic migratory erythema may cause marked morbidity and is frequently misdiagnosed. A 42-year-old white woman with a 1½-year history of refractory dermatitis (most severe on the lower extremities) had the glucagonoma syndrome. Her severe morbidity was markedly relieved with the administration of intravenous amino acids. This therapy was successful in controlling the necrolytic migratory erythema through recurrences after somatostatin (SMS 201-995), surgical debulking, and chemotherapy proved inadequate.

UR - http://www.scopus.com/inward/record.url?scp=0026056087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026056087&partnerID=8YFLogxK

U2 - 10.1016/0190-9622(91)70285-A

DO - 10.1016/0190-9622(91)70285-A

M3 - Article

C2 - 1761771

AN - SCOPUS:0026056087

SN - 0190-9622

VL - 25

SP - 925

EP - 928

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 5

ER -

Treatment of necrolytic migratory erythema in glucagonoma syndrome

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this